Literature DB >> 10498200

Sodium channel activity and sigma binding of 2-aminopropanamide anticonvulsants.

P Pevarello1, A Bonsignori, C Caccia, R Amici, R A McArthur, R G Fariello, P Salvati, M Varasi.   

Abstract

Sodium channel blocking, anticonvulsant activity, and sigma (sigma) binding of selected leads in a series of alpha-amino amide anticonvulsants were examined. While anticonvulsant compounds were always endowed with low micromolar sodium (Na+) channel site-2 binding, compounds with low site-2 Na+ channel affinity failed to control seizures. No correlation could be drawn with sigma1 binding. Both anticonvulsant and Na+ channel blocking activities were independent of stereochemistry, while sigma1 binding seems to be favoured by an S-configuration on the aminoamide moiety.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10498200     DOI: 10.1016/s0960-894x(99)00415-1

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  5 in total

1.  Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.

Authors:  Yuying Wang; Sarah M Wilson; Joel M Brittain; Matthew S Ripsch; Christophe Salomé; Ki Duk Park; Fletcher A White; Rajesh Khanna; Harold Kohn
Journal:  ACS Chem Neurosci       Date:  2011-06-15       Impact factor: 4.418

2.  Merging the structural motifs of functionalized amino acids and alpha-aminoamides: compounds with significant anticonvulsant activities.

Authors:  Christophe Salomé; Elise Salomé-Grosjean; James P Stables; Harold Kohn
Journal:  J Med Chem       Date:  2010-05-13       Impact factor: 7.446

3.  Xadago (Safinamide): A Monoamine Oxidase B Inhibitor for the Adjunct Treatment of Motor Symptoms in Parkinson's Disease.

Authors:  Martin Paspe Cruz
Journal:  P T       Date:  2017-10

Review 4.  Investigational agents in the treatment of Parkinson's disease: focus on safinamide.

Authors:  Naveed M Malek; Donald G Grosset
Journal:  J Exp Pharmacol       Date:  2012-08-14

5.  Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease.

Authors:  Luca Loprete; Chiara Leuratti; Carlo Cattaneo; Mita M Thapar; Colm Farrell; Marco Sardina
Journal:  Pharmacol Res Perspect       Date:  2016-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.